XTL Biopharmaceuticals Ltd. (XTLB)Healthcare | Biotechnology | Herzliya, Israel | NasdaqCM
2.88 USD
-0.03
(-1.031%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:25 a.m. EDT
The immediate outlook is clouded by severe technical weakness and a lack of liquidity, despite a recent spike in volume following the Psyga Bio acquisition. While the stock has rallied off its lows, it remains trapped below critical moving averages, with the 50-day line acting as heavy resistance and the 200-day line sitting significantly higher, indicating a long-term downtrend that recent gains have not yet reversed. The trading volume is abnormally thin relative to the average, suggesting a lack of genuine institutional interest and making price discovery difficult. Fundamentally, the picture is dire: the company is burning through cash with negative free cash flow and operating cash flow, while holding a precarious balance sheet with a current ratio well below 1.0. The recent acquisition adds complexity rather than clarity, and the history shows a pattern of sharp declines followed by volatile recoveries, often ending lower. With no dividend to provide income and a business model reliant on future drug approvals that have historically failed to materialize into sustained growth, the investment case is currently non-existent. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.130777 |
| AutoARIMA | 0.131304 |
| AutoETS | 0.131394 |
| AutoTheta | 0.186369 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 0.13 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 0.99 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 7,077,493 |
| Beta | 0.55 |
| Website | https://www.xtlbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5582822 |
| Address1 | 85 Medinat Hayehudim St. |
| All Time High | 2,400.0 |
| All Time Low | 2.01 |
| Ask | 3.54 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 389,550 |
| Average Daily Volume3 Month | 2,016,259 |
| Average Volume | 2,016,259 |
| Average Volume10Days | 389,550 |
| Beta | 0.551 |
| Bid | 1.99 |
| Bid Size | 2 |
| Book Value | -0.0 |
| City | Herzliya |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.88 |
| Current Ratio | 0.395 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.895 |
| Day Low | 2.75 |
| Display Name | XTL Biopharmaceuticals |
| Dividend Date | 1,486,684,800 |
| Ebitda | -1,266,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.53 |
| Enterprise Value | 7,001,494 |
| Eps Trailing Twelve Months | -0.36 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.6584 |
| Fifty Day Average Change | 0.22160006 |
| Fifty Day Average Change Percent | 0.08335843 |
| Fifty Two Week Change Percent | -55.82822 |
| Fifty Two Week High | 10.28 |
| Fifty Two Week High Change | -7.3999996 |
| Fifty Two Week High Change Percent | -0.71984434 |
| Fifty Two Week Low | 2.01 |
| Fifty Two Week Low Change | 0.8700001 |
| Fifty Two Week Low Change Percent | 0.43283588 |
| Fifty Two Week Range | 2.01 - 10.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,125,581,400,000 |
| Float Shares | 828,780 |
| Free Cashflow | -2,116,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.38461 |
| Held Percent Institutions | 0.03075 |
| Implied Shares Outstanding | 2,457,463 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,774,396,800 |
| Last Split Factor | 1:4 |
| Long Business Summary | XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel. |
| Long Name | XTL Biopharmaceuticals Ltd. |
| Market | us_market |
| Market Cap | 7,077,493 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_36775 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -759,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,587,954 |
| Open | 2.89 |
| Operating Cashflow | -1,025,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.27 |
| Phone | 972 5 4228 8897 |
| Pre Market Change | -0.27000022 |
| Pre Market Change Percent | -9.375008 |
| Pre Market Price | 2.61 |
| Pre Market Time | 1,784,034,201 |
| Previous Close | 2.91 |
| Price Hint | 4 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.181 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -1.03093 |
| Regular Market Day High | 2.895 |
| Regular Market Day Low | 2.75 |
| Regular Market Day Range | 2.75 - 2.895 |
| Regular Market Open | 2.89 |
| Regular Market Previous Close | 2.91 |
| Regular Market Price | 2.88 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 5,576 |
| Return On Assets | -0.2101 |
| Return On Equity | -0.29299 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,457,463 |
| Shares Percent Shares Out | 0.0038 |
| Shares Short | 9,362 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 9,750 |
| Short Name | XTL Biopharmaceuticals Ltd. |
| Short Percent Of Float | 0.0050999997 |
| Short Ratio | 0.05 |
| Source Interval | 15 |
| Symbol | XTLB |
| Total Cash | 76,000 |
| Total Cash Per Share | 0.031 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.29315 |
| Two Hundred Day Average Change | -0.41314983 |
| Two Hundred Day Average Change Percent | -0.12545735 |
| Type Disp | Equity |
| Volume | 5,576 |
| Website | https://www.xtlbio.com |
| Zip | 4,676,670 |